## INCY: Incyte Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.3% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($96.04)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)**
- Source: Markets Financial Content | 20251203T213000 | Somewhat-Bullish | Relevance: 99%
- Incyte Corporation announced equity inducement awards granted to Richard Hoffman, its new Executive Vice President and General Counsel. These awards, approved by the compensation committee, are an inducement for his employment in accordance with Nasdaq Listing Rule 5635(c)(4) and include stock options, restricted stock units, and performance shares.

**2. Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - December 3, 2025**
- Source: BioSpace | 20251204T101641 | Neutral | Relevance: 99%
-  Incyte Corporation announced equity inducement awards to Richard Hoffman, their new Executive Vice President and General Counsel, under Nasdaq Listing Rule 5635(c)(4). These awards, effective December 1, 2025, include stock options, restricted stock units, and performance shares, designed to incentivize his employment. The grants are part of the Companyâ€™s 2024 Inducement Stock Incentive Plan.

**3. Insider Selling: Incyte (NASDAQ:INCY) EVP Sells 20,105 Shares of Stock**
- Source: MarketBeat | 20251204T223551 | Neutral | Relevance: 99%
-  Incyte (NASDAQ:INCY) EVP Steven Stein sold 20,105 shares of the company's stock for over $2 million, representing a 24.15% reduction in his holdings. This sale occurred just after Incyte reported strong Q3 earnings, beating analyst expectations with $2.26 EPS and $1.37 billion in revenue. Analyst sentiment for Incyte is currently mixed, with a "Hold" consensus rating and a target price of $93.85.

**4. Norges Bank Takes $96.78 Million Position in Incyte Corporation $INCY**
- Source: MarketBeat | 20251204T120953 | Bullish | Relevance: 99%
-  Norges Bank has acquired a new position in Incyte Corporation (NASDAQ: INCY), purchasing 1,421,080 shares valued at approximately $96.78 million, representing about 0.73% of the company. This move follows Incyte's strong quarterly performance, where it exceeded EPS estimates and saw a 20% year-over-year revenue increase. Despite several analyst upgrades to "buy" ratings and increased price targets, MarketBeat's consensus remains a "Hold" with an average target of $93.85.

**5. Insider Selling: Incyte (NASDAQ:INCY) EVP Sells 2,559 Shares of Stock**
- Source: MarketBeat | 20251204T223551 | Neutral | Relevance: 98%
-  Incyte (NASDAQ:INCY) EVP Steven Stein sold 2,559 shares of the company's stock on December 1st at an average price of $102.96, totaling $263,474.64. This transaction reduced his stake by 2.49% to 100,327 shares. The biopharmaceutical company recently exceeded Q3 earnings and revenue estimates, and analysts currently hold a consensus "Hold" rating with a target price of $93.85.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Morgan Stanley | $92 | $86 | +7% |
| 2025-12-08 | Wells Fargo | $116 | $97 | +20% |
| 2025-12-08 | Mizuho | $121 | $90 | +34% |
| 2025-11-24 | Barclays | $115 | $101 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Wells Fargo | main | Overweight |
| 2025-12-08 | Mizuho | up | Outperform |
| 2025-11-24 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.20M) |
| Sells | 13 ($23.25M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Baker Bros. Advisors: 15.7% (0.0%)
- Vanguard Group Inc: 10.2% (-0.9%)
- Blackrock Inc.: 9.1% (-0.3%)
- Dodge & Cox Inc.: 7.1% (-4.5%)
- State Street Corpora: 4.9% (-2.0%)

### Key Risks

1. Heavy insider selling: $23M sold (13 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +19%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.13 indicates undervaluation relative to growth. Quality metrics strong (ROE 30%, ROA 14%, margin 25%). Balance sheet: strong liquidity (3.2x), low leverage (D/E 0.36). Analyst sentiment positive (4 raises, avg +19%). Insider selling cluster ($23.2M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.7B |
| Beta | 0.81 |
| 52W Range | $53.56 - $109.28 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.13 |
| Forward P/E | 13.4 |
| Current P/E | 15.0 |
| YoY Growth | 12.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -3.7% to -2.3% (+1.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.3pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.3%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.34x) but short-term weakness (below SMA20). MACD histogram bearish (-0.97), momentum weakening. RSI neutral at 55.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.29% (CS: 30) | Weak |
| RSI_14 | 54.8 | Neutral |
| MACD Histogram | -0.97 | Bearish |
| vs SMA20 | 0.985x | Below |
| vs SMA50 | 1.074x | Above |
| vs SMA200 | 1.339x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $102.52
- **Stop Loss:** $96.04 (6.3% risk)
- **Target:** $109.00 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 77
- **Position Value:** $7,894.04
- **Portfolio %:** 7.89%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-09 (Est: $1.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.64 | $2.26 | +38.0% |
| 2025Q2 | $1.47 | $1.57 | +6.6% |
| 2025Q1 | $1.03 | $1.16 | +12.3% |
| 2024Q4 | $1.55 | $1.43 | -8.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*